Journal of Allergy and Clinical Immunology Global · 2023 · 44 citations · 27 references
Life SciencesDermatologyImmunologyAllergyHypersensitivityImmunopharmacologyAllergic Skin DiseasesAtopic DermatitisContact DermatitisDrug AllergyPatch TestingAtopic Dermatitis ImmunopathologyAtopic Dermatitis PathogenesisAtopic Dermatitis PharmacotherapyAtopic Dermatitis TreatmentAtopic Inflammation
Background: Telazorlimab is a humanized anti-OX40 monoclonal antibody being studied for treatment of T-cell-mediated diseases. Objective: This randomized, placebo-controlled, phase 2b dose-range finding study investigated efficacy, safety, pharmacokinetics, and immunogenicity of telazorlimab in subjects with atopic dermatitis. Methods: In this 2-part study (NCT03568162), adults (≥18 years) with moderate-to-severe disease were randomized to various regimens of subcutaneous telazorlimab or placebo for 16 weeks' blinded treatment, followed by 38 weeks' open-label treatment and 12 weeks' drug-free follow-up. Telazorlimab treatment groups (following a loading dose) in part 1 were 300 mg every 2 weeks; 300 mg every 4 weeks; or 75 mg every 4 weeks. Part 2 evaluated telazorlimab 600 mg every 2 weeks. The primary end point was percentage change from baseline in Eczema Area and Severity Index (EASI) at week 16. Safety assessments included incidence of treatment-emergent adverse events. Results: = .008 for both). Telazorlimab was well tolerated, with similar distribution of adverse events between telazorlimab- and placebo-treated subjects in both part 1 and part 2. Conclusion: Telazorlimab, administered subcutaneously at 300 mg every 2 weeks or 600 mg every 2 weeks following a loading dose, was well tolerated and induced significant and progressive clinical improvement in adults with moderate-to-severe atopic dermatitis.
27
World Medical Association Declaration of Helsinki
JAMA · 2013 · 29.4K citations
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson, Thomas Bieber, Emma Guttman‐Yassky et al. · New England Journal of Medicine · 2016 · 2K citations · Full text
Medicine, Dermatology, Immunology +12
Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham et al. · The Lancet · 2017 · 1.2K citations · Full text
Medicine, Dermatology, Immunology +17
Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky et al. · British Journal of Dermatology · 2020 · 595 citations · Full text